Insilico's AI-Designed Rentosertib Shows Lung Function Improvement in IPF Phase IIa

The GENESIS-IPF trial delivers the first clinical proof-of-concept for a fully AI-discovered drug: rentosertib, a TNIK inhibitor designed by Insilico Medicine's Chemistry42 platform, demonstrates dose-dependent FVC improvement in idiopathic pulmonary fibrosis patients. Phase IIb is underway.